MLTX
MoonLake Immunotherapeutics
11.40$
-0.3%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +5.3% | +7.1% | -3.4% | -4.9% | -7.8% | +7.0% | -10.0% | -9.9% | +2.4% | -5.7% | +43.4% | |
| – | +2.8% | +7.7% | -3.0% | -4.6% | -7.4% | +6.7% | -10.0% | -9.7% | +2.5% | -5.9% | +43.7% | |
| – | +41.8% | +1.6% | -25.2% | +9.6% | -52.0% | +50.5% | +12.9% | +14.4% | -4.6% | -10.8% | +60.1% | |
| – | +3.0% | +7.1% | -5.0% | -5.0% | -9.3% | +7.2% | -11.5% | -10.5% | +3.5% | -9.1% | +50.0% | |
| – | +46.6% | +41.5% | +12.1% | +43.5% | +18.1% | +5.1% | +14.1% | +18.0% | +21.1% | +18.4% | +13.8% | |
| – | +23.4% | -10.1% | +26.6% | +53.0% | +8.1% | +302.1% | +3.5% | +20.5% | -2.6% | +22.0% | -0.4% | |
| – | -3.3% | -10.6% | +37.8% | +63.5% | +11.9% | +6.8% | +14.1% | +76.8% | -6.0% | +1.4% | -1.6% | |
| – | +666.2% | +8.9% | +1.3% | +32.6% | -21.7% | +4.4% | +8.2% | -3.3% | -17.7% | -25.4% | +35.4% | |
| – | +77.8% | +110.6% | +54.2% | +115.8% | -15.4% | +15.9% | +48.0% | +60.0% | +19.3% | -17.8% | -27.1% | |
| – | – | – | – | – | – | – | +0.5% | +0.5% | +0.5% | +33.6% | +0.5% | |
| – | +16.6% | +9.5% | -4.0% | -6.2% | -8.5% | -8.8% | -13.2% | -18.3% | +5.4% | -16.6% | +68.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +12.0% | +4.5% | +0.4% | +0.0% | +0.3% | +0.3% | +0.1% | +0.1% | +1.7% | +10.6% | +3.7% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.